Taladegib: Phase I started

Ignyta said Cancer Research UK (London, U.K.) began an open-label, dose-escalation, dose-expansion, U.K. Phase I trial to evaluate oral taladegib plus weekly paclitaxel. Ignyta has exclusive, worldwi...